Share.trading.guru you are absolutely right. Below is a paper recently published on its efficacy on children with a 100% and earlier seroconversion rate. Imagine every new born child in the world being vaccinated against Hep B with this vaccine. This vaccine could potentially mean the global eradication of this virus and if WHO get involved, this will likely be another success story next to the global eradication of polio.
Vaccine. Oct 12;20(1-2):92-7. Related Articles, Links
Antibody responses to preS components after immunization of children with low doses of BioHepB.
Madalinski K, Sylvan SP, Hellstrom U, Mikolajewicz J, Zembrzuska-Sadkowska E, Piontek E.
Department of Immunology, Child Health Memorial Institute, Al. Dzieci Polskich 20, 04-736, Warsaw, Poland. [email protected]
BioHepB is a recombinant, hepatitis B vaccine derived from a mammalian cell line and containing HBs as well as preS1 and preS2 antigens, in their glycosylated and non-glycosylated forms. The vaccine was administered intramuscularly to 18 children aged 5 months to 11 years at 0, 1 and 6 months. One hundred percent seroconversion and seroprotection rates were achieved after primary and secondary immunization with the 2.5 microg doses of BioHepB.Ten out of the 18 children (56%) responded with the appearance of anti-preS1 and/or anti-preS2 antibodies in circulation, when analyzed 1, 2, 6, 7 and 12 months after the initiation of vaccination. In comparison with the emergence of the anti-HBs response, early (month 2, after two injections) or late (month 7, after three injections) peak responses were noted for the kinetics of anti-preS1 and anti-preS2 production during the course of immunization, demonstrating that the anti-preS1 and anti-preS2 responses are differently regulated, compared with the anti-HBs response. At month 6, just prior to the final injection, BioHepB caused significantly higher anti-HBs responses (GMT) in preS1-reactive children than in children without preS1 antibodies (P<0.005). Moreover, a significantly higher, anti-HBs response in GMT was also noted for anti-preS2-reactive children compared with anti-preS2-negative children (P<0.05). These findings demonstrated that recognition of the preS epitopes contained in the experimental preS1/preS2/S vaccine is accompanied by a more rapid onset and pronounced antibody response to the S-gene-derived protein in healthy children.
SIE Price at posting:
0.0¢ Sentiment: None Disclosure: Not Held
